Free Trial

Vertex Pharmaceuticals (VRTX) Competitors

Vertex Pharmaceuticals logo
$452.16 +6.96 (+1.56%)
Closing price 07/1/2025 04:00 PM Eastern
Extended Trading
$453.20 +1.03 (+0.23%)
As of 08:58 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

VRTX vs. AMGN, GILD, REGN, ALNY, BIIB, INCY, UTHR, NBIX, EXEL, and BMRN

Should you be buying Vertex Pharmaceuticals stock or one of its competitors? The main competitors of Vertex Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Incyte (INCY), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Exelixis (EXEL), and BioMarin Pharmaceutical (BMRN). These companies are all part of the "biotechnology" industry.

Vertex Pharmaceuticals vs. Its Competitors

Amgen (NASDAQ:AMGN) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings.

Amgen has a net margin of 17.39% compared to Vertex Pharmaceuticals' net margin of -8.91%. Amgen's return on equity of 176.11% beat Vertex Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Amgen17.39% 176.11% 12.39%
Vertex Pharmaceuticals -8.91%-3.36%-2.42%

Amgen currently has a consensus target price of $307.82, indicating a potential upside of 5.95%. Vertex Pharmaceuticals has a consensus target price of $511.62, indicating a potential upside of 13.15%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Vertex Pharmaceuticals is more favorable than Amgen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amgen
2 Sell rating(s)
12 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.35
Vertex Pharmaceuticals
0 Sell rating(s)
14 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.54

Amgen has higher revenue and earnings than Vertex Pharmaceuticals. Vertex Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$33.42B4.67$4.09B$10.9626.51
Vertex Pharmaceuticals$11.02B10.54-$535.60M-$3.92-115.35

In the previous week, Amgen had 14 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 65 mentions for Amgen and 51 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 1.12 beat Amgen's score of 0.99 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Amgen
47 Very Positive mention(s)
1 Positive mention(s)
10 Neutral mention(s)
2 Negative mention(s)
3 Very Negative mention(s)
Positive
Vertex Pharmaceuticals
32 Very Positive mention(s)
0 Positive mention(s)
12 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

76.5% of Amgen shares are owned by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. 0.7% of Amgen shares are owned by insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Amgen has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500.

Summary

Amgen beats Vertex Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get Vertex Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for VRTX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VRTX vs. The Competition

MetricVertex PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$114.33B$2.85B$5.48B$8.94B
Dividend YieldN/A2.69%5.38%4.12%
P/E Ratio-115.3521.1726.2219.74
Price / Sales10.54262.85394.92109.12
Price / CashN/A41.8936.4957.06
Price / Book7.107.237.915.37
Net Income-$535.60M-$55.05M$3.15B$248.34M
7 Day Performance1.42%-0.60%0.75%1.67%
1 Month Performance1.51%3.77%3.46%4.56%
1 Year Performance-4.56%2.20%34.60%18.42%

Vertex Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VRTX
Vertex Pharmaceuticals
4.7266 of 5 stars
$452.16
+1.6%
$511.62
+13.2%
-4.1%$114.33B$11.02B-115.356,100Positive News
AMGN
Amgen
4.3174 of 5 stars
$273.01
-5.6%
$309.22
+13.3%
-6.6%$146.97B$33.42B24.9428,000
GILD
Gilead Sciences
4.843 of 5 stars
$106.05
-2.3%
$110.55
+4.2%
+62.8%$131.77B$28.75B22.3017,600Positive News
Insider Trade
REGN
Regeneron Pharmaceuticals
4.9403 of 5 stars
$511.30
+0.3%
$836.48
+63.6%
-49.4%$55.16B$14.20B13.0115,106Analyst Downgrade
ALNY
Alnylam Pharmaceuticals
4.2888 of 5 stars
$312.99
+1.1%
$319.58
+2.1%
+32.4%$40.82B$2.25B-149.602,230Positive News
Analyst Forecast
BIIB
Biogen
4.9742 of 5 stars
$124.68
-1.9%
$188.19
+50.9%
-43.9%$18.21B$9.68B12.277,605
INCY
Incyte
4.3669 of 5 stars
$67.28
-1.7%
$74.53
+10.8%
+12.9%$13.01B$4.41B210.112,617
UTHR
United Therapeutics
4.9941 of 5 stars
$286.48
-1.5%
$393.08
+37.2%
-8.8%$12.89B$2.88B11.401,305Positive News
Analyst Forecast
NBIX
Neurocrine Biosciences
4.9388 of 5 stars
$125.73
-0.7%
$162.00
+28.9%
-8.6%$12.43B$2.36B42.581,800Positive News
EXEL
Exelixis
4.7384 of 5 stars
$43.40
+7.5%
$41.00
-5.5%
+96.0%$11.82B$2.17B19.711,147Positive News
Analyst Forecast
Gap Up
High Trading Volume
BMRN
BioMarin Pharmaceutical
4.9455 of 5 stars
$53.99
-1.8%
$93.45
+73.1%
-31.6%$10.34B$2.95B20.043,040

Related Companies and Tools


This page (NASDAQ:VRTX) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners